News & AnalysisAffyImmune Therapeutics scores $30mAffyImmune Therapeutics Inc, a clinical stage biotechnology company, has raised $30 million in funding.ByIris Dorbian7 October 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs